What Happens If You Take Too Much Tirzepatide: Symptoms, Timeline, and Emergency Protocol

Reviewed by FormBlends Medical Team · Last updated September 2026 · Sources listed below

Key Takeaways

• The most frequently reported symptoms in U.S. poison-center GLP-1 exposures are nausea (17.4 percent of cases), vomiting (13.9 percent), diarrhea (3.4 percent) and abdominal pain (3.3 percent); hypoglycemia occurred in 2.4 percent (Gaw et al., Journal of Medical Toxicology, 2024). Tirzepatide reaches peak blood levels at a median of 24 hours, range 8 to 72 hours (label, revised 08/2026)
• There is no reversal agent. The label says treatment is supportive and that a period of observation may be necessary, taking into account tirzepatide's half-life of approximately 5 days (Zepbound and Mounjaro labels, section 10, revised 08/2026)
• Any dose above what you were prescribed is a dosing error. The label directs you to contact the Poison Help Line (1-800-222-1222) or a medical toxicologist; they decide whether you can be observed at home or need to be seen
• Of 5,713 single-substance GLP-1 exposures reported to U.S. poison centers from 2017 through 2022, 22.4 percent were evaluated in a health care facility, 5.3 percent were admitted, and 79.9 percent were therapeutic errors such as taking a dose twice (Gaw 2024)

The short answer

Taking too much tirzepatide most often causes nausea and vomiting; in poison-center data hypoglycemia is uncommon (2.4 percent of GLP-1 cases overall, though 22.1 percent of those admitted to hospital; Gaw 2024). Blood levels peak at a median of 24 hours and the half-life is about 5 to 6 days, so symptoms can persist for days (label, revised 08/2026). There is no antidote and treatment is supportive. Call the Poison Help Line at 1-800-222-1222 as soon as you realize the error, tell your prescriber, and call 911 for confusion, seizure, fainting or vomiting you cannot control. Correction, September 2026: the hour-by-hour percentages that appeared on earlier versions of this page could not be traced to any published source and have been removed.

Table of contents

1. How tirzepatide overdose actually happens
2. The symptom timeline: what to expect hour by hour
3. The hypoglycemia risk most articles underestimate
4. What most articles get wrong about "flushing the system"
5. The decision tree: when to monitor at home vs. when to go to the ER
6. Real overdose case patterns from compounded tirzepatide programs
7. Step-by-step: what to do in the first 30 minutes after realizing the error
8. The 72-hour monitoring protocol for at-home management
9. Why repeat overdoses are more dangerous than single events
10. Prevention strategies that actually work
11. What poison centers see with GLP-1 dosing errors
12. The label's overdose instructions
13. Restarting at your old dose after a break
14. FAQ
15. Sources

How tirzepatide overdose actually happens

Tirzepatide overdose falls into four distinct failure modes, each with different risk profiles:

Mode 1: Dose-dial error. Selecting 10 mg on a compounded vial syringe when you meant 5 mg, or dialing 15 mg on a multi-dose pen when prescribed 7.5 mg. In the poison-center series, 79.9 percent of GLP-1 exposures were therapeutic errors: taking a dose twice (29.8 percent), another incorrect dose (21.9 percent) and doses too close together (17.7 percent) (Gaw et al., 2024). Correction, September 2026: a 60 percent figure and a citation to Kalra et al., Diabetes Therapy 2024, previously appeared here; the article could not be found and the figure has been removed.

Mode 2: Concentration confusion. Injecting from a 10 mg/mL vial when you thought it was 5 mg/mL. If you draw "0.5 mL" thinking you're getting 2.5 mg but the vial is actually 10 mg/mL, you've injected 5 mg, double your intended dose. This error is unique to compounded formulations where patients manage their own reconstitution or switch between vial concentrations.

Mode 3: Double-injection within the same week. Forgetting you already took your weekly dose and injecting again 2 to 4 days later. Tirzepatide's 5-day half-life means the first dose is still circulating at 70% of peak concentration when the second dose arrives, creating an additive effect.

Mode 4: Titration schedule misunderstanding. Jumping from 2.5 mg to 10 mg because you misread the titration calendar, skipping the 5 mg and 7.5 mg steps. This isn't technically an overdose relative to the maximum approved dose (15 mg), but it's an overdose relative to your tolerance, which is what determines symptom severity.

FDA reports that as of May 31, 2026 it had received more than 730 adverse-event reports involving compounded tirzepatide (and 990 for compounded semaglutide), some involving hospitalization, and that dosing errors included patients drawing the wrong volume, clinicians miscalculating conversions, and prescriptions above labeled doses (FDA, content current as of September 1, 2026). FDA's July 26, 2024 alert described patients who injected 5 to 20 times the intended dose because of confusion between units and milliliters. Correction, September 2026: an earlier version of this page cited a FAERS count of 1,247 dosing errors with 34 percent needing emergency evaluation; that figure could not be verified and has been removed.

The symptom timeline: what to expect hour by hour

Tirzepatide is a long-acting GIP/GLP-1 receptor agonist with an elimination half-life of approximately 5 to 6 days and a median time to peak concentration of 24 hours, range 8 to 72 hours (Zepbound label section 12.3, revised 08/2026). Correction, September 2026: an earlier version of this section gave an hour-by-hour overdose timeline with percentages. No published tirzepatide overdose time course exists, and the timeline has been replaced with what is actually documented.

What is documented. Peak blood levels arrive at a median of 24 hours after injection, so symptoms from an excess dose can build through the first day and persist for several days as the drug clears over a half-life of about 5 to 6 days (label). In the poison-center series of 5,713 GLP-1 exposures, the reported effects were nausea in 17.4 percent, vomiting in 13.9 percent, diarrhea in 3.4 percent, abdominal pain in 3.3 percent and hypoglycemia in 2.4 percent; 6.2 percent had a serious outcome and there was one death, from stercoral colitis and bowel ischemia (Gaw et al., 2024; tirzepatide was grouped with other agents). Lilly's medical information page (reviewed August 18, 2026) states there is no published tirzepatide overdose case series and that management is supportive.

What is not documented. No hour-by-hour onset, no percentage of overdoses that vomit, no typical day of resolution. Anyone giving you those numbers for tirzepatide is guessing.

The hypoglycemia risk most articles underestimate

The label puts hypoglycemia risk where the data are: in the type 2 diabetes study, blood glucose below 54 mg/dL occurred in 10.3 percent of patients also taking a sulfonylurea versus 2.1 percent without one, and in the obesity study of people without diabetes, in 0.3 percent of Zepbound patients (sections 5 and 6.1, revised 08/2026). In poison-center GLP-1 exposures, hypoglycemia was recorded in 2.4 percent of all cases but 22.1 percent of those admitted to hospital (Gaw 2024). Correction, September 2026: an earlier version cited a 12 percent hypoglycemia rate from a 2024 surveillance study by Lingvay et al.; that study could not be found and the figure has been removed.

The mechanism: tirzepatide stimulates insulin secretion in a glucose-dependent manner, meaning it shouldn't cause hypoglycemia when glucose is normal. But in overdose, two factors override that safety mechanism:

1. Severe nausea prevents oral intake. If you can't eat for 18 to 36 hours and your liver glycogen stores deplete, glucose drops regardless of insulin levels.

1. Other glucose-lowering medication. Insulin or a sulfonylurea taken alongside tirzepatide is the strongest documented risk factor for hypoglycemia (label, sections 5 and 6.1). A previously stated mechanism involving GIP receptor overactivation came from animal data and has been removed.

Hypoglycemia symptoms in this context include shakiness, confusion, sweating, irritability, and in severe cases, loss of consciousness or seizure. The confusion is particularly dangerous because patients often attribute it to dehydration or nausea rather than low blood sugar, delaying treatment.

The monitoring rule: there is no published home glucose-check schedule for a tirzepatide overdose, so follow the instructions Poison Control (1-800-222-1222) or your clinician gives you. Shakiness, sweating, confusion or a meter reading below 70 mg/dL are reasons to call back or seek care right away, and the worst published case, a 39-year-old who restarted at 12.5 mg after a month off and was found four days later with a glucose of 1.5 mmol/L (27 mg/dL), spent 25 days in intensive care (Sharafeldin et al., Cureus 2025).

What most articles get wrong about "flushing the system"

The most common piece of bad advice circulating in patient forums and low-quality health content: "drink lots of water to flush the medication out faster."

Tirzepatide is cleared by metabolism, not by the kidneys filtering intact drug, and its half-life is approximately 5 to 6 days regardless of how much you drink (label section 12.3, revised 08/2026). Drinking extra water does not speed clearance and, in the context of severe vomiting, large volumes of plain water can worsen electrolyte imbalance. Fluids matter for preventing dehydration, not for removing the drug.

The second myth: activated charcoal. Charcoal binds drugs in the GI tract, but tirzepatide is injected subcutaneously. By the time you realize you've overdosed, the medication is already systemically absorbed. Charcoal does nothing.

The third myth: "induce vomiting to get it out." Vomiting doesn't remove subcutaneously injected medication. It only worsens dehydration and esophageal irritation.

What actually helps: small, frequent sips of electrolyte solution (Pedialyte, Gatorade, or homemade oral rehydration solution: 1 liter water, 6 teaspoons sugar, 0.5 teaspoon salt). Anti-nausea medication only if a clinician prescribes it for you. Rest in a semi-recumbent position. Glucose monitoring. That's it. There is no shortcut to clearance.

The decision tree: when to monitor at home vs. when to go to the ER

The label's instruction is simpler than any home framework: in case of overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist (Zepbound and Mounjaro labels, section 10). Poison Control, not a dose multiple, decides whether you stay home or go in. The steps below are what to have ready for that call. Correction, September 2026: an earlier version presented this as an in-house FormBlends framework with numeric thresholds; those thresholds had no published basis and have been removed.

Step 1: Quantify the overdose.

• What dose did you inject?
• What dose were you prescribed?
• Have both numbers ready for Poison Control. There is no published dose multiple that separates home observation from emergency care.

Step 2: Assess current symptoms (within 6 hours of injection).

• Tell Poison Control exactly what you feel: nausea, vomiting and how many times, dizziness, confusion, abdominal pain, any glucose reading.
• Severe or repeated vomiting, confusion, fainting, seizure, or a glucose reading below 70 mg/dL are reasons to seek emergency care while you call.

Step 3: Assess risk factors.

• Say whether you take insulin, a sulfonylurea or any other glucose-lowering drug; the label identifies these as the main hypoglycemia risk.
• Mention any history of pancreatitis, gastroparesis or severe gastrointestinal disease, pregnancy or breastfeeding, and whether you are alone.

Step 4: If monitoring at home, set check-in intervals.

• Follow the monitoring plan Poison Control or your clinician gives you rather than a fixed schedule from a web page.
• Call 911 for confusion, seizure, chest pain, severe abdominal pain, or inability to keep fluids down.

Step 5: Contact your prescribing provider within 2 hours of the overdose regardless of symptom severity. Document the error, the dose taken, and the monitoring plan. The provider may prescribe antiemetics or adjust your next scheduled dose.

Label text, Zepbound and Mounjaro (revised 08/2026), section 10: in the event of overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist; appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms; a period of observation and treatment may be necessary, taking into account the half-life of tirzepatide of approximately 5 days.

Real overdose case patterns from compounded tirzepatide programs

FDA and poison-center reports describe recurring error patterns that do not match the textbook picture of a single large overdose. Three that appear in FDA's July 26, 2024 alert, the poison-center error categories (Gaw 2024) and the Washington Poison Center's summary (data through September 2025):

Pattern 1: The "catch-up" overdose. Patient misses a weekly dose, feels fine, then injects the missed dose 3 days late while keeping the next scheduled dose on time. Result: two doses 4 days apart instead of 7. With a half-life of about 5 to 6 days, much of the first dose is still on board when the second arrives. Doses taken too close together were 17.7 percent of poison-center GLP-1 therapeutic errors (Gaw 2024). The label's rule is to take a missed dose within 4 days and otherwise skip it (section 2.3).

Pattern 2: The vial-swap error. Patient has two vials in the fridge, one at 5 mg/mL for a 2.5 mg dose (0.5 mL draw) and one at 10 mg/mL for a 5 mg dose (also 0.5 mL draw). Grabs the wrong vial, draws the habitual 0.5 mL, and injects 5 mg instead of 2.5 mg. This error is invisible until symptoms start because the syringe volume looks correct. Prevention requires labeling vials with both concentration and color-coded tape.

Pattern 3: The units-versus-milliliters error. FDA's July 26, 2024 alert describes patients told to draw, for example, 5 units (0.05 mL) who drew 50 units instead, and clinicians who miscalculated milligram-to-unit conversions, producing doses 5 to 20 times what was intended. The Washington Poison Center reports that about half of its GLP-1 calls involve compounded vials and this units-versus-mL confusion (data through September 2025). A wrong reconstitution volume produces the same effect on every dose until the vial runs out.

The common thread: these are system errors, not knowledge errors. The patients understood dosing principles but failed at the execution step. The fix is procedural (checklists, labeling, single-vial protocols) rather than educational.

Step-by-step: what to do in the first 30 minutes after realizing the error

Time-stamped protocol for the immediate post-overdose window:

Minute 0: Stop and confirm.

• Do not inject again.
• Do not induce vomiting.
• Confirm what you actually injected: check the vial label, the syringe markings, and your dosing log.
• Calculate the actual dose in mg.

Minute 2: Check baseline glucose.

• If you have a glucose meter, check now and write down the number.
• If you don't have a meter, say so when you call Poison Control; do not delay the call to buy one.

Minute 5: Call your prescribing provider.

• Call the Poison Help Line at 1-800-222-1222 first if you cannot reach your prescriber; it is staffed around the clock.
• Report: (1) prescribed dose, (2) actual dose injected, (3) time of injection, (4) current symptoms.
• Ask whether to monitor at home or go to ER.

Minute 10: Set up your monitoring station.

• Gather: glucose meter, test strips, electrolyte drinks, small bland snacks (crackers, toast), a bowl (in case of vomiting), phone charger.
• Write down the monitoring plan Poison Control or your clinician gave you and set reminders for it.
• If you live alone, text a friend or family member the situation and ask them to check in every 6 hours.

Minute 15: Start a symptom log.

• Use your phone's notes app or a paper notebook.
• Log format: [Time] [Glucose reading] [Symptoms] [Intake/output].
• Example: "14:30 | 102 mg/dL | Mild nausea, no vomiting | Sipped 4 oz Pedialyte."

Minute 20: Begin oral hydration.

• Sip 2 to 4 oz of electrolyte solution every 30 minutes.
• Do not chug. Rapid intake on an irritated stomach triggers vomiting.
• If nausea worsens with drinking, switch to ice chips.

Minute 30: Reassess and decide.

• Follow the plan you were given. If you were told you can stay home, keep hydrating in small sips and rest.
• If any red flag develops (confusion, seizure, fainting, chest pain, severe abdominal pain, inability to keep fluids down), call 911.

The 72-hour monitoring protocol for at-home management

Correction, September 2026: an earlier version of this section gave a 72-hour schedule of glucose checks, fluid volumes, calorie targets and activity milestones tied to a dose multiple. None of it came from a published source. What the label supports is simpler.

If Poison Control or your clinician clears you to stay home, the label's framework is supportive care and observation for a period that reflects tirzepatide's half-life of approximately 5 days (section 10). In practice that means small frequent sips of fluid, rest, checking glucose if you have a meter and were told to, and re-contacting Poison Control or your clinician if symptoms change. Confirm with your prescriber when to take your next dose; the label gives no rule for dosing after an extra dose.

Red flags that override the protocol at any point:

• Glucose below 70 mg/dL despite carb intake.
• Vomiting more than 5 times in 12 hours.
• No urination for 12 hours (sign of severe dehydration).
• Confusion, slurred speech, or difficulty staying awake.
• Severe abdominal pain (could indicate pancreatitis, a rare but serious tirzepatide complication).

Why repeat overdoses are more dangerous than single events

A single accidental overdose, while unpleasant, rarely causes lasting harm in otherwise healthy patients. The body tolerates a one-time GLP-1 receptor overstimulation, symptoms resolve as the drug clears, and most patients return to their regular titration schedule without issue.

Repeat overdoses, whether from persistent dosing errors or intentional off-protocol use, create three compounding risks:

Risk 1: Repeated errors mean a repeating cause. Correction, September 2026: an earlier version described a tolerance effect and cited a 2023 study by Wadden et al. in Obesity; that study could not be found and the claim has been removed. What is documented is that therapeutic errors made up 79.9 percent of poison-center GLP-1 exposures (Gaw 2024), so a second error usually points to a fixable process problem, not bad luck.

Risk 2: Gastroparesis. GLP-1 receptor agonists used for weight loss have been associated with gastroparesis, pancreatitis and bowel obstruction in a large claims analysis (Sodhi et al., JAMA 2023). That study did not examine overdose or repeated errors, and the vagus-nerve mechanism described in an earlier version of this page had no source and has been removed.

Risk 3: Pancreatitis. Acute pancreatitis is a labeled warning for tirzepatide, and the label says to discontinue the drug if pancreatitis is suspected (Warnings and Precautions, revised 08/2026). FDA's July 26, 2024 alert lists acute pancreatitis among events reported after compounded GLP-1 dosing errors. Correction, September 2026: a cumulative-inflammation claim and a citation to Azoulay et al., JAMA Internal Medicine 2023, previously appeared here; the article could not be found and both have been removed.

If you've had two or more overdose events in a 3-month period, that's a system failure requiring intervention. Options include switching to pre-filled pens (if available and affordable), moving to a lower-concentration vial to reduce the impact of volume errors, or implementing a witnessed-injection protocol where a family member verifies the dose before each injection.

Prevention strategies that actually work

The FormBlends 5-Point Injection Safety Checklist, designed specifically for compounded tirzepatide programs:

1. Single-vial rule. Keep only one active vial in your fridge at a time. When you receive a new vial at a different concentration or dose, finish or discard the old one before starting the new one. FDA's 2024 alert and poison-center reports identify concentration confusion as a recurring cause of overdose.

2. Label everything. Use a permanent marker or printed label on every vial: "5 mg/mL, draw 0.5 mL for 2.5 mg dose." Include the concentration, the volume to draw, and the resulting dose in mg. Update the label if your dose changes.

3. Pre-draw verification. Before drawing from the vial, say out loud: "I am prescribed [X] mg. This vial is [Y] mg/mL. I need to draw [Z] mL." Verbal confirmation catches mental autopilot errors.

4. Post-draw verification. After drawing, hold the syringe up to light and confirm the volume against the markings. Take a photo with your phone if you're uncertain. Compare to the last dose photo.

5. Injection log. Immediately after injecting, log the date, time, dose, and injection site in a dedicated notebook or app. Before each injection, check the log to confirm you haven't already dosed that week.

Bonus strategy for high-risk patients: use a medication timer cap that displays the time since the vial was last opened. If the cap says "3 days" and you're on a weekly schedule, you know you already dosed.

When you should NOT manage an overdose at home

Steelmanning the contrary view: the home monitoring protocol above assumes a low-risk patient with a moderate overdose and reliable support. That's not everyone.

You should go directly to the ER, not attempt home monitoring, if:

• Poison Control (1-800-222-1222) tells you to be seen. Their triage, not a dose multiple, is the standard.
• You have a history of pancreatitis, gastroparesis, or inflammatory bowel disease.
• You're on insulin, sulfonylureas, or SGLT2 inhibitors (hypoglycemia risk is much higher).
• You're pregnant or breastfeeding (no safety data for tirzepatide overdose in pregnancy).
• You live alone with no one to check on you and no reliable way to get to the ER if symptoms worsen.
• You have a history of severe medication reactions or anaphylaxis.
• You cannot keep fluids down, or you have confusion, fainting or seizure.

A thoughtful clinician might also argue that any overdose warrants ER evaluation simply because the cost of missing a serious complication (pancreatitis, severe hypoglycemia) is so high. The counterargument is that ER visits for low-risk overdoses consume resources, expose patients to hospital-acquired infections, and often result in observation-only care that the patient could have done at home.

The decision comes down to risk tolerance and access to follow-up care. If you have a responsive provider who can check in every 6 hours and escalate if needed, home monitoring is reasonable for low-to-moderate overdoses. If you don't have that level of support, err toward the ER.

What poison centers actually see with GLP-1 dosing errors (2017 to 2025 data)

The only published epidemiology of GLP-1 overdose comes from U.S. poison centers. Gaw and colleagues analyzed 5,713 single-substance GLP-1 receptor agonist exposures reported from 2017 through 2022 (Journal of Medical Toxicology, February 2024). Tirzepatide was grouped with other agents, so the figures describe the class.

Measure	Figure
Exposures that were therapeutic errors	79.9%
Took a dose twice	29.8% of exposures
Other incorrect dose	21.9%
Doses too close together	17.7%
Nausea	17.4%
Vomiting	13.9%
Diarrhea	3.4%
Abdominal pain	3.3%
Hypoglycemia	2.4% of all cases; 22.1% of hospitalized cases
Evaluated in a health care facility	22.4%
Admitted	5.3%
Serious outcome	6.2%
Deaths	1 (stercoral colitis and bowel ischemia)
Exposure rate	1.16 per million in 2017 to 6.32 per million in 2022; up 80.9 percent from 2021 to 2022

Volume has kept climbing. The Washington Poison Center reports national GLP-1 poison-center cases of about 2,500 in 2022, 4,700 in 2023, 8,500 in 2024 and 10,745 through September 2025, with ten-fold overdoses from drawing errors, daily-instead-of-weekly dosing, and roughly half of its own calls involving compounded vials and units-versus-mL confusion; hypoglycemia appeared in 3.4 percent of that center's GLP-1 exposures.

Sources: Gaw et al., J Med Toxicol 2024 (PMC); Washington Poison Center, GLP-1 insights; Poison Control, tirzepatide for weight loss.

The label's overdose instructions, quoted (Zepbound and Mounjaro, revised August 2026)

Section 10 of both tirzepatide labels is short. In the event of overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist. Appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days. Lilly's medical information page (last reviewed August 18, 2026) adds that no overdose case series has been published and that management is supportive.

The pharmacokinetics that frame that observation period, from section 12.3: median time to peak concentration 24 hours (range 8 to 72 hours); half-life approximately 5 to 6 days; steady state after 4 weekly doses. On low blood sugar, section 6.1 reports glucose below 54 mg/dL in 10.3 percent of type 2 diabetes patients also taking a sulfonylurea versus 2.1 percent without, and in 0.3 percent of Zepbound patients in the obesity study of people without diabetes. Section 2.3 gives the only scheduling rule: a missed dose may be taken within 4 days (96 hours), otherwise skip it.

Sources: Zepbound prescribing information, 08/2026; Mounjaro prescribing information, 08/2026; Lilly Medical, treating a Zepbound overdose, reviewed August 18, 2026.

Why restarting at your old dose after a break is the dangerous case

The most severe published tirzepatide case did not involve a mis-drawn syringe. A 39-year-old who had been self-administering tirzepatide stopped for about a month, then resumed at 12.5 mg. Four days later the patient was found confused with a capillary glucose of 1.5 mmol/L (about 27 mg/dL), a Glasgow Coma Scale score of 9, ketoacidosis and severe potassium, magnesium and phosphate depletion, and spent 25 days in intensive care with mechanical ventilation, renal replacement therapy and a tracheostomy before a prolonged rehabilitation (Sharafeldin et al., Cureus 2025). The label's escalation scheme exists because tolerance to tirzepatide's effects builds gradually; a full maintenance dose after weeks off behaves more like a first dose at five times the starting strength.

The same logic applies to the units-versus-milliliters errors in FDA's July 26, 2024 alert, where patients injected 5 to 20 times the intended dose. If you have had a gap in treatment, ask your prescriber what dose to restart at before you inject; do not assume your old dose.

Sources: Sharafeldin et al., Cureus 2025 (PMC); FDA dosing-error alert, July 26, 2024.

FAQ

What is considered an overdose of tirzepatide?

Any dose higher than your prescribed dose is a dosing error, and the label directs you to contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for every one (Zepbound and Mounjaro labels, section 10, revised 08/2026). No published threshold separates a minor error from an emergency; poison-center data show most GLP-1 exposures were managed without admission (5.3 percent admitted), but Poison Control makes that call, not a multiplier.

Can you die from a tirzepatide overdose?

Deaths are rare. Among 5,713 single-substance GLP-1 exposures reported to U.S. poison centers from 2017 through 2022 there was one death, from stercoral colitis and bowel ischemia, and 6.2 percent had a serious outcome (Gaw et al., 2024); no tirzepatide-specific death appears in the accessible literature as of September 5, 2026. The worst published tirzepatide case involved 25 days in intensive care after severe hypoglycemia (Cureus 2025). Most overdoses resolve with supportive care.

How long does tirzepatide overdose last?

No published study gives a symptom timeline for tirzepatide overdose. The label reports peak blood levels at a median of 24 hours (range 8 to 72) and a half-life of approximately 5 to 6 days, and its overdosage section says observation may be needed with that half-life in mind (revised 08/2026). Drug remains measurable for several half-lives after symptoms settle.

Is there an antidote for tirzepatide overdose?

No. There is no reversal agent or antidote. Treatment is entirely supportive: IV fluids for dehydration, antiemetics for nausea, glucose for hypoglycemia, and monitoring for complications. The medication must clear naturally through metabolic degradation.

Should I skip my next dose after an overdose?

Ask Poison Control or your prescriber; do not decide alone. The label's only scheduling rule covers missed doses (take within 4 days, otherwise skip; section 2.3) and gives no instruction for what to do after an extra dose, so the timing of your next injection should come from the clinician who knows exactly what you took. Never try to "make up" for a skipped dose by doubling the next one.

What if I accidentally injected twice in one week?

Call the Poison Help Line (1-800-222-1222) and your prescriber. Taking a dose twice was the single most common GLP-1 therapeutic error reported to poison centers (29.8 percent of errors), and doses too close together accounted for another 17.7 percent (Gaw 2024). Poison Control sets the monitoring; your prescriber sets the next dose. Most patients tolerate this error without ER-level complications, but monitoring is essential.

Can I go to urgent care instead of the ER for an overdose?

Urgent care can assess you and start treatment (IV fluids, antiemetics), but they typically can't provide extended observation. Poison Control (1-800-222-1222) will tell you which setting fits your situation; there is no published dose multiple that separates urgent care from the emergency department. Confusion, seizure, fainting or uncontrolled vomiting mean the ER.

Does drinking water help flush out tirzepatide faster?

No. Tirzepatide is not renally cleared, so hydration status doesn't affect clearance rate. Drinking electrolyte solution helps prevent dehydration from vomiting, but it doesn't speed up how fast the drug leaves your system. The half-life is approximately 5 to 6 days regardless of hydration (label section 12.3).

What are the first signs of tirzepatide overdose?

Nausea is the most frequently reported effect in poison-center GLP-1 cases (17.4 percent), followed by vomiting (13.9 percent) (Gaw 2024). No published source gives an hour-by-hour onset for tirzepatide; the label places peak blood levels at a median of 24 hours after injection, with a range of 8 to 72 hours. Some patients report a "heavy" or "full" feeling in the stomach even without eating.

Can tirzepatide overdose cause permanent damage?

In most cases, no. Symptoms resolve completely as the drug clears. The exceptions are rare complications like pancreatitis (which can cause permanent pancreatic damage) or aspiration pneumonia from severe vomiting. Single accidental overdoses in otherwise healthy patients rarely cause lasting harm.

How do I know if my blood sugar is too low after an overdose?

Symptoms of hypoglycemia include shakiness, sweating, confusion, irritability, rapid heartbeat, and hunger (though the hunger may be masked by nausea). If you have a glucose meter, a reading below 70 mg/dL confirms hypoglycemia. If you don't have a meter but experience these symptoms, consume 15 grams of fast-acting carbs (4 oz juice, 4 glucose tablets, 1 tablespoon honey) and seek medical attention if symptoms don't improve in 15 minutes.

What should I eat after a tirzepatide overdose?

For the first 24 hours, focus on hydration (electrolyte drinks, clear broth) rather than food. When nausea starts to improve (usually 24 to 48 hours), introduce bland carbs: crackers, toast, plain rice, bananas, applesauce. Avoid high-fat and high-fiber foods for 3 to 5 days as they slow gastric emptying and can worsen nausea. Small frequent meals (every 2 to 3 hours) are better tolerated than three large meals.

How many adverse-event reports has FDA received for compounded tirzepatide?

More than 730 as of May 31, 2026, alongside 990 for compounded semaglutide, according to FDA's page on unapproved GLP-1 drugs (content current as of September 1, 2026). FDA notes that compounding pharmacies are not required to report adverse events, so the true count is likely higher, and that reported dosing errors included patients drawing the wrong volume and clinicians miscalculating conversions, with some hospitalizations.

Is low blood sugar common after taking too much tirzepatide?

It is uncommon unless another glucose-lowering drug is involved. In poison-center GLP-1 exposures, hypoglycemia was recorded in 2.4 percent of all cases but 22.1 percent of hospitalized ones (Gaw 2024). The Zepbound label reports glucose below 54 mg/dL in 0.3 percent of patients without diabetes, and 10.3 percent of type 2 diabetes patients also taking a sulfonylurea versus 2.1 percent without (revised 08/2026). Severe cases have occurred, including a 25-day ICU stay (Cureus 2025).

What does the tirzepatide label say to do after an overdose?

Section 10 of the Zepbound and Mounjaro labels (revised 08/2026) says to contact the Poison Help Line at 1-800-222-1222 or a medical toxicologist, start supportive treatment according to the patient's signs and symptoms, and allow for a period of observation that takes into account tirzepatide's half-life of approximately 5 days. There is no antidote. Lilly's medical information page, reviewed August 18, 2026, confirms that no overdose case series has been published.

Related guides

• What Happens If You Take Too Much Semaglutide? A Clinical Timeline and Emergency Response Guide
• What Happens If You Take Too Much Ozempic? Symptoms, Treatment, and Prevention
• What Happens If I Inject Too Much Semaglutide? Medical Response Timeline and Safety Protocol
• What to Do If You Take Too Much Semaglutide: The Complete Clinical Response Protocol
• Can You Overdose on Semaglutide? Understanding Toxicity Risk and What to Do If You Take Too Much
• How Much Tirzepatide to Take: The Evidence-Based Dosing Protocol from Starting Dose to Maintenance
• Tool: dosage calculator

Sources

1. Gaw CE, Lee EE, Osterhoudt KC, et al. Glucagon-like peptide-1 receptor agonist exposures reported to United States poison centers, 2017 to 2022. Journal of Medical Toxicology. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10959851/ (Replaces an unverifiable Kalra 2024 citation, September 2026.)
2. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of September 1, 2026 (730+ compounded tirzepatide adverse-event reports as of May 31, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
3. Urva S, Coskun T, Loghin C, et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2020. doi 10.1111/dom.14110. (Corrected journal and year, September 2026.)
4. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
5. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026, sections 2.3, 5, 6.1, 10 and 12.3. https://pi.lilly.com/us/zepbound-uspi.pdf (Replaces an unverifiable Lingvay 2024 citation, September 2026.)
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Diabetes. 2022;71(6):1236-1247.
7. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403-1413.
8. Sharafeldin M, et al. Severe hypoglycemia and ketoacidosis after self-administered tirzepatide resumed at 12.5 mg. Cureus. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12683422/ (Replaces an unverifiable Wadden 2023 citation, September 2026.)
9. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. doi 10.1001/jama.2023.19574. (Corrected journal and year, September 2026.)
10. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded (Replaces an unverifiable Azoulay 2023 citation, September 2026.)
11. Heinemann L et al. Insulin pen user errors: a systematic review and meta-analysis. Journal of Diabetes Science and Technology. 2023;17(3):678-691.
12. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS clinical trial program. Diabetes Care. 2023;46(Suppl 1):S188-S197.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021;46:101102.
14. Eli Lilly and Company, Lilly Medical. How do you treat a Zepbound (tirzepatide) overdose? Date of last review August 18, 2026. https://medical.lilly.com/us/products/answers/how-do-you-treat-a-zepbound-tirzepatide-overdose-211010
15. Gaw CE, Lee EE, Osterhoudt KC, et al. Glucagon-like peptide-1 receptor agonist exposures reported to United States poison centers, 2017 to 2022. Journal of Medical Toxicology. February 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10959851/
16. Sharafeldin M, et al. Case report: severe hypoglycemia, ketoacidosis and electrolyte depletion after self-administered tirzepatide resumed at 12.5 mg. Cureus. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12683422/
17. Washington Poison Center. GLP-1s: what poison centers are seeing (national case counts through September 2025). https://www.wapc.org/insights/glp-1s/
18. Poison Control (America's Poison Centers). Tirzepatide for weight loss: what to do if you take too much. https://www.poison.org/articles/tirzepatide-for-weight-loss
19. Eli Lilly and Company, Lilly Medical. How do you treat a Zepbound (tirzepatide) overdose? Date of last review August 18, 2026. https://medical.lilly.com/us/products/answers/how-do-you-treat-a-zepbound-tirzepatide-overdose-211010
20. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026, section 10. https://pi.lilly.com/us/mounjaro-uspi.pdf
21. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. All references to brand-name medications are for educational comparison only.